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Backgrounds
Infliximab (IFX) potently suppresses ocular attacks in Beh-
cet’s disease (BD) with uveitis, resulting in favorable long-
term visual prognosis. However, about one third of the
patients had ocular attacks one or two weeks before the
next IFX infusion, suggesting that the efficacy of IFX
depends on the concentration. This study investigates IFX
trough levels and antibody toward IFX (ATI) in BD
patients receiving IFX and analyzes the relationship of the
pharmacokinetics with clinical efficacy.
Objective
To investigate effects of infliximab (IFX) trough levels
and antibody toward IFX (ATI) on efficacy and adverse
events in Behçet’s disease (BD) patients receiving IFX.
Patients and methods
A total of 160 BD patients who were or had been
receiving IFX were enrolled (male 115, age 43.2+ 12.1 y.
o.) from 10 institutes in Japan. The primary target was
eye in 135 patients including 8 patients who previously
discontinued IFX, intestine in 18, and CNS in 7. After
initial boosting, IFX was given every 8 weeks but the
interval was shortened when clinical efficacy was insuffi-
cient. The trough level was measured in sera from 122
patients with uveitis when 5mg/kg of IFX was adminis-
tered with 5 to 10 week interval, whereas ATI was
determined by ELISA in all patients. The patient condi-
tions at sampling were divided into the symptomatic
phase when the patients had any of symptoms due to
BD except oral aphthae, and the asymptomatic phase
when the patients were asymptomatic. Patients were
classified into 5 groups according to physicians’ global
assessment of IFX efficacy for uveitis; Group A: very
effective, B: effective, C: insufficient, D; ineffective, and
E: discontinued the IFX.
Results
Mean serum IFX trough level was 4.4+ 4.7mg/ml in 430
samples from 122 patients. The level was significantly
lower in symptomatic phase (n=73, 2.5±5.3 μg/ml) than
in the asymptomatic phase (n=357, 4.9 ± 4.6μg/ml).
ROC analysis determined the cut-off level was 0.93μg/
ml. Patient-based analysis revealed that the trough level
was lower in Group C+D (1.3±3.3μg/ml) than Group A
(4.2±4.4μg/ml) and B (5.4±5.7μg/ml), whereas adminis-
tration interval was significantly shorter in Group B
(7.2±1.1 wk) and C+D (6.8±1.5 wk) than Group A
(8.2±0.9 wk). ATI(+) was found in 18 (11.3%) of all
patients. The frequency was significantly higher in
Group C+D (5/10, 50%) and E (4/8, 50%) than Group A
(3/75, 4%) and B (6/38, 16%). Thus, unfavorable clinical
responses were associated with low trough level and
positive ATI. Muitivariate analysis using logistic regres-
sion model revealed association of therapeutic failure
(Group C+D and E) with female, positive ATI, and infu-
sion reaction (IR). Moreover, ATI was strongly asso-
ciated with IR. We found that shortening administration
intervals restored IFX level with clinical efficacy in 2
ATI positive patients, whereas switching to adalimumab
was successful in 2 patients having serious IR.
Conclusion
ATI is associated with reduced efficacy due to decreased
IFX trough level, and IR. When IFX efficacy is reduced,
shortening IFX administration intervals restores clinical1Yokohama City University Graduate School of Medicine, Department of
Internal Medicine and Clinical Immunology, Yokohama, Japan
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efficacy in most of patients but other therapeutic option
such as adalimumab is necessary in a part of the patients.
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